Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic effects of atazanavir/ritonavir versus darunavir/ritonavir with tenofovir/emtricitabine in treatment-naive HIV-1 patients
2010-021002-38Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) comparing Atazanavir/ritonavir + tenofovir/emtricitabine with Darunavir/ritonavir + tenofovir/emtricitabine (2 arms). Primary endpoint: Change from baseline in total cholesterol at Week 24. Started Sep 2010; status: completed.
02
Drugs
atazanavirdarunavirritonavirtenofovir disoproxil fumarateemtricitabine
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-021002-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021002-38.